Biotechnology company Monte Rosa Therapeutics has announced it will work with pharmaceutical company Novartis on the development of novel degraders for immune-mediated diseases.   As part of the collaboration, Monte Rosa and Novartis will look to accelerate the development of degraders for important immune-mediated diseases driven by highly credentialed and difficult-to-drug targets. Monte Rosa will apply […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!